COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

-2.85%

Decreased from previous period

Revenue decline while Healthcare median is 0.00%. Seth Klarman would investigate if market share loss is temporary.

Cost of Revenue Growth

-2.97%

Decreased from previous period

Cost reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive advantage potential.

Gross Profit Growth

-2.33%

Decreased from previous period

Gross profit decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

Gross Margin Ratio Growth

0.53%

Increased from previous period

Margin change of 0.53% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

12.87%

Increased from previous period

Other expenses change of 12.87% versus flat Healthcare costs. Walter Schloss would verify efficiency.

Operating Expenses Growth

2.76%

Decreased from previous period

Operating expenses change of 2.76% versus flat Healthcare costs. Walter Schloss would verify control.

Total Costs & Expenses Growth

-2.03%

Decreased from previous period

Total costs reduction while Healthcare median is 0.71%. Seth Klarman would investigate advantages.

Interest Expense Growth

-5.56%

Decreased from previous period

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

5.15%

Increased from previous period

D&A growth exceeding 1.5x Healthcare median of 0.77%. Jim Chanos would check for overinvestment.

EBITDA Growth

-12.82%

Decreased from previous period

EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EBITDA Margin Growth

-10.26%

Decreased from previous period

EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Income Growth

-23.85%

Decreased from previous period

Operating income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Margin Growth

-21.62%

Decreased from previous period

Operating margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Other Income/Expenses Growth

13.16%

Increased from previous period

Other expenses change of 13.16% versus flat Healthcare. Walter Schloss would verify control.

Pre-Tax Income Growth

-21.37%

Decreased from previous period

Pre-tax income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Pre-Tax Margin Growth

-19.06%

Decreased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

-20.17%

Decreased from previous period

Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Net Income Growth

-21.96%

Decreased from previous period

Net income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Net Margin Growth

-19.67%

Increased from previous period

Net margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EPS Growth

-22.00%

Decreased from previous period

EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Diluted EPS Growth

-22.00%

Decreased from previous period

Diluted EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Share Count Growth (Basic)

0.06%

Share count reduction below 50% of Healthcare median of 0.09%. Jim Chanos would check for issues.

Share Count Growth (Diluted)

0.06%

Diluted share reduction below 50% of Healthcare median of 0.05%. Jim Chanos would check for issues.

Select Chart Metric:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

-2.85%

Decreased from previous period

Revenue decline while Healthcare median is 0.00%. Seth Klarman would investigate if market share loss is temporary.

Cost of Revenue Growth

-2.97%

Decreased from previous period

Cost reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive advantage potential.

Gross Profit Growth

-2.33%

Decreased from previous period

Gross profit decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

Gross Margin Ratio Growth

0.53%

Increased from previous period

Margin change of 0.53% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

12.87%

Increased from previous period

Other expenses change of 12.87% versus flat Healthcare costs. Walter Schloss would verify efficiency.

Operating Expenses Growth

2.76%

Decreased from previous period

Operating expenses change of 2.76% versus flat Healthcare costs. Walter Schloss would verify control.

Total Costs & Expenses Growth

-2.03%

Decreased from previous period

Total costs reduction while Healthcare median is 0.71%. Seth Klarman would investigate advantages.

Interest Expense Growth

-5.56%

Decreased from previous period

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

5.15%

Increased from previous period

D&A growth exceeding 1.5x Healthcare median of 0.77%. Jim Chanos would check for overinvestment.

EBITDA Growth

-12.82%

Decreased from previous period

EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EBITDA Margin Growth

-10.26%

Decreased from previous period

EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Income Growth

-23.85%

Decreased from previous period

Operating income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Margin Growth

-21.62%

Decreased from previous period

Operating margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Other Income/Expenses Growth

13.16%

Increased from previous period

Other expenses change of 13.16% versus flat Healthcare. Walter Schloss would verify control.

Pre-Tax Income Growth

-21.37%

Decreased from previous period

Pre-tax income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Pre-Tax Margin Growth

-19.06%

Decreased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

-20.17%

Decreased from previous period

Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Net Income Growth

-21.96%

Decreased from previous period

Net income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Net Margin Growth

-19.67%

Increased from previous period

Net margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EPS Growth

-22.00%

Decreased from previous period

EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Diluted EPS Growth

-22.00%

Decreased from previous period

Diluted EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Share Count Growth (Basic)

0.06%

Share count reduction below 50% of Healthcare median of 0.09%. Jim Chanos would check for issues.

Share Count Growth (Diluted)

0.06%

Diluted share reduction below 50% of Healthcare median of 0.05%. Jim Chanos would check for issues.

Select Chart Metric: